FDA Grants Fast Track Status to UVI Plus Checkpoint Inhibition for Melanoma Subgroup
Source: Targeted Oncology, October 2021
The FDA has granted a fast track designation to UV1, a universal cancer vaccine, in combination with either pembrolizumab (Keytruda) or ipilimumab (Yervoy) for the treatment of unresectable or metastatic melanoma, according to a press release by Ultimovacs.1
